S. 79 · 118th Congress · Senate

Interagency Patent Coordination and Improvement Act of 2023

Active· Placed on Senate Legislative Calendar under General Orders. Calendar No. 18.
Introduced
Jan 25, 23
Passed Senate
Pending
Passed House
Pending
Sent to President
Pending
Signed into Law
Pending

Executive Summary

Interagency Patent Coordination and Improvement Act of 2023

This bill establishes the Interagency Task Force on Patents to support coordination and communication between the U.S. Patent and Trademark Office (PTO) and the Food and Drug Administration (FDA) on activities relating to patents for human drugs and biological products.

The task force's duties shall include sharing information about (1) the processes of each agency, including how each agency evaluates applications (e.g., patent applications at the PTO and new drug applications at the FDA); and (2) new approvals of patents, human drugs, biological products, and new technologies. The task force must also establish a process that requires (1) the PTO to request from the FDA information relating to certain patent applications to help patent examiners carry out their duties, (2) the FDA to provide such information to the PTO, and (3) the PTO to assist the FDA in its ministerial role of listing patents.

Previous Versions

00Jan 25, 2023

Interagency Patent Coordination and Improvement Act of 2023

This bill establishes the Interagency Task Force on Patents to support coordination and communication between the U.S. Patent and Trademark Office (PTO) and the Food and Drug Administration (FDA) on activities relating to patents for human drugs and biological products.

The task force's duties shall include sharing information about (1) the processes of each agency, including how each agency evaluates applications (e.g., patent applications at the PTO and new drug applications at the FDA); and (2) new approvals of patents, human drugs, biological products, and new technologies. The task force must also establish a process that requires (1) the PTO to request from the FDA information relating to certain patent applications to help patent examiners carry out their duties, (2) the FDA to provide such information to the PTO, and (3) the PTO to assist the FDA in its ministerial role of listing patents.

Action Timeline

6
  1. MAR 01, 2023Committee

    Committee on the Judiciary

    Reported by Senator Durbin without amendment. Without written report.

  2. MAR 01, 2023Committee

    Committee on the Judiciary

    Reported by Senator Durbin without amendment. Without written report.

  3. MAR 01, 2023Calendars

    Placed on Senate Legislative Calendar under General Orders. Calendar No. 18.

  4. FEB 09, 2023Committee

    Committee on the Judiciary

    Ordered to be reported without amendment favorably.

  5. JAN 25, 2023IntroReferral

    Introduced in Senate

  6. JAN 25, 2023IntroReferral

    Read twice and referred to the Committee on the Judiciary.

Committees

3

Judiciary Committee

ssju00

Referred: Mar 1, 2023

Active

Judiciary Committee

ssju00

Referred: Feb 9, 2023

Active

Judiciary Committee

ssju00

Referred: Jan 25, 2023

Active